How Does Dr. Reddy's Laboratories Company Sell Its Products and Services?

Target: hospitals, payers, and group purchasing organizations in the US and Europe. These customers drive volume for biosimilars in oncology and immunology where Dr. Reddy's emphasizes quality, regulatory compliance, and cost savings to win tenders and formulary placement.

Target: Indian and Russian outpatient markets via branded generics. The company leans on trusted brand names, wide pharmacy distribution, and an extensive medical representative network to capture chronic-care prescriptions and retail share.

Target: consumers seeking nicotine replacement and nutraceuticals (Celevida). After the USD 630,000,000 acquisition of a nicotine replacement therapy portfolio, Dr. Reddy's frames itself as a holistic health partner, selling through e-commerce, pharmacies, and retail chains.

Target: multinational pharma firms and biosimilar partners for contract manufacturing and licensing deals. These B2B relationships use the company's API and finished-dose capabilities and support export-led growth.

Dr. Reddy's positions itself as a value-driven, quality-focused pharma and wellness provider: affordable branded generics in emerging markets, competitive biosimilars in regulated markets, and consumer health for wellness growth.

Message: cost-effective alternatives with regulatory rigor and trusted brands. The company leverages a diversified distribution network, direct sales force, and third-party distributors to reach hospitals, pharmacies, and consumers, supporting tenders, retail sales, and e-commerce channels.

Dr. Reddy's sales channels mix direct sales (US specialty, hospitals), B2B distribution (wholesalers, tenders), and partner-led retail in India; biosimilars use hybrid B2B plus specialty pharmacy partnerships to convert prescribers.

Commodity generics price to win volume; complex generics and biosimilars capture premium pricing on limited-competition molecules and first-to-file exclusivity; US specialty direct channels drive higher margins with controlled pricing.

First-to-file US regulatory wins, limited-competition targets, a direct US specialty force (>70 percent revenue in specialty markets), and physician-facing megabrand marketing in India convert attention into prescriptions and tenders.

Megabrand physician loyalty and patient stickiness in India, long-term hospital contracts, tender repeat business, and substitution-driven biosimilar uptake sustain recurring sales and upsell to higher-value biologics.

Strong product mix shift to complex injectables and specialty care, plus integration of the NRT business and GLP-1 pipeline (semaglutide) drive future sales and pricing power. Diversified geographic channels-India, US, Europe, and exports-lower concentration risk.

Dr. Reddy's sales channels combine a direct sales force and medical representatives, third-party distributors in India, tender procurement capabilities for government contracts, and growing e-commerce/online pharmacy partnerships, supporting both B2B and B2C reach.

Main risks are the Revlimid revenue cliff with negligible generic lenalidomide sales through December 2026, delayed approvals or uptake of the three key biosimilars, and execution risk on 25+ US launches planned for 2025-2026. Pricing pressure and tender competition can hit margins.

Outlook for 2026 is positive: the firm is pivoting from bulk supplier to integrated healthcare provider with specialty launches and digital offerings likely to sustain double-digit growth as the new portfolio matures.